C
C. Lance Cowey
Researcher at University of North Carolina at Chapel Hill
Publications - 22
Citations - 6777
C. Lance Cowey is an academic researcher from University of North Carolina at Chapel Hill. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 8, co-authored 12 publications receiving 5651 citations. Previous affiliations of C. Lance Cowey include Baylor University.
Papers
More filters
Journal ArticleDOI
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma.
James Larkin,Vanna Chiarion-Sileni,Rene Gonzalez,Jean-Jacques Grob,C. Lance Cowey,Christopher D. Lao,Dirk Schadendorf,Reinhard Dummer,Michael Smylie,Piotr Rutkowski,Pier Francesco Ferrucci,A. Hill,John Wagstaff,Matteo S. Carlino,John B A G Haanen,Michele Maio,Ivan Marquez-Rodas,Grant A. McArthur,Paolo A. Ascierto,Georgina V. Long,Margaret K. Callahan,Michael A. Postow,Michael A. Postow,Kenneth F. Grossmann,Mario Sznol,Brigitte Dréno,Lars Bastholt,Arvin Yang,Linda Rollin,Christine Horak,F. Stephen Hodi,Jedd D. Wolchok,Jedd D. Wolchok +32 more
TL;DR: Among previously untreated patients with metastatic melanoma, nivolumab alone or combined with ipilimumab resulted in significantly longer progression-free survival than ipILimumab alone, and in patients with PD-L1-negative tumors, the combination of PD-1 and CTLA-4 blockade was more effective than either agent alone.
Journal ArticleDOI
Neoadjuvant Clinical Trial With Sorafenib for Patients With Stage II or Higher Renal Cell Carcinoma
C. Lance Cowey,Chirag Amin,Raj S. Pruthi,Eric Wallen,Matthew E. Nielsen,Gayle Grigson,Cathy Watkins,Keith V. Nance,Jeffrey M. Crane,Mark Jalkut,Dominic Moore,William Y. Kim,Paul A. Godley,Young E. Whang,Julia R. Fielding,W. Kimryn Rathmell +15 more
TL;DR: The administration of preoperative sorafenib therapy can impact the size and density of the primary tumor and appears safe and feasible.
Journal ArticleDOI
VHL gene mutations in renal cell carcinoma: role as a biomarker of disease outcome and drug efficacy.
TL;DR: The potential role of VHL mutation by mutation, loss of heterozygosity, and promoter methylation has been found to be important to RCC pathogenesis.
Journal ArticleDOI
The loss of radiographic enhancement in primary renal cell carcinoma tumors following multitargeted receptor tyrosine kinase therapy is an additional indicator of response.
TL;DR: Intratumoral changes in computed tomography enhancement after receptor tyrosine kinase inhibition correlate with primary tumor response, and may be a useful adjunct to the standard response evaluation criteria in solid tumors (RECIST criteria) in assessing response to therapy.
Journal ArticleDOI
Primary renal cell carcinoma: Relationship between 18F-FDG uptake and response to neoadjuvant sorafenib
TL;DR: Primary ccRCC tumors with lower SUVbase are more likely to respond to neoadjuvant sorafenib, whereas this trend was not observed for non-ccR CC tumors.